Large randomized controlled trials (RCTs) have authenticated principally the role of anti-VEGF agents in age-related macular degeneration, retinal vascular occlusion, and diabetic macular edema [46–49]. This evidence concerns the gene VEGFA and retinal vascular occlusion.